RLD strength for BE study [Design Issues]

posted by Brus – Spain, 2021-01-21 14:24 (480 d 05:07 ago) – Posting: # 22186
Views: 1,308

Dear Colleagues,

We are developing a generic of an RLD with two strengths (100 mg and 50 mg).

But viewing the dosage regimen of reference drug product, it would make sense to develop a 150 mg strength even though the reference product does not have it. So, our generic drug product will have 3 strengths (150, 100 and 50 mg).

What dose should the BE study be done with? (PK linearity has been demonstrated in the range of that doses).

Should RLD 100mg VS Generic 100mg be done or RLD 100mg + RLD 50mg VS generic 150mg?

Best regards,

Complete thread:

UA Flag
Activity
 Admin contact
22,074 posts in 4,629 threads, 1,565 registered users;
online 14 (0 registered, 14 guests [including 13 identified bots]).
Forum time: Monday 20:31 CEST (Europe/Vienna)

Rules are for the guidance of wise men
and the blind obedience of fools.    attributed to Solon

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5